Abstract
Atacicept (TACI:Fc5) is a homodimeric fusion protein obtained through recombinant DNA technology being developed by Merck Serono SA, under license from ZymoGenetics Inc, for the potential treatment of B-cell diseases. Atacicept is undergoing phase II/III clinical trials for systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, as well as for several B-cell malignancies.
MeSH terms
-
Animals
-
Arthritis, Rheumatoid / drug therapy
-
Clinical Trials as Topic
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Lupus Erythematosus, Systemic / drug therapy
-
Lymphoma, B-Cell / drug therapy
-
Multiple Myeloma / drug therapy
-
Recombinant Fusion Proteins / therapeutic use*
-
Structure-Activity Relationship
Substances
-
Recombinant Fusion Proteins
-
TACI receptor-IgG Fc fragment fusion protein